Targeted Oncology17h
Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBC
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...
Targeted Oncology5h
Updated Zanidatamab Data Shows Durable Response in Biliary Tract Cancer
Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...
Targeted Oncology21h
The Real-World Challenges of Cell and Gene Therapy in Oncology
Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...
Targeted Oncology23h
TNBC Vaccine Shows Promising Safety, Immune Response in Phase 1 Trial
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety ...